Markets:

Overview

News

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

38.21 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday ↗

December 24, 2025

Two analysts waxed bullish on the future of the company.

Via The Motley Fool

Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Momentum and Technical Setup for Growth Investors ↗

December 18, 2025

Travere Therapeutics (TVTX) shows strong earnings momentum, a bullish technical uptrend, and a current consolidation phase, presenting a potential breakout setup for growth investors.

Via Chartmill

Travere Therapeutics Inc (NASDAQ:TVTX) Screened as a High Growth Momentum Stock with Strong Technical Setup ↗

November 27, 2025

Travere Therapeutics (TVTX) shows strong high-growth momentum with surging sales and a positive technical setup, signaling a potential breakout.

Via Chartmill

Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗

November 18, 2025

Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model.

Via Investor's Business Daily

This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗

November 18, 2025

A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year.

Via The Motley Fool

Topics Regulatory Compliance

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Preview: Travere Therapeutics ↗

August 05, 2025

Via Benzinga

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗

November 18, 2025

A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals.

Via The Motley Fool

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Top 2% Travere Looks To Top Buy Zone After Screaming Up Another Beat ↗

October 31, 2025

The stock popped Friday — poising itself to top a buy zone — on another sales beat from its linchpin drug.

Via Investor's Business Daily

Topics Earnings

Travere Therapeutics Inc (NASDAQ:TVTX) Q3 2025 Earnings Soar, Fueled by FILSPARI Sales and Milestone Payments ↗

October 30, 2025

Travere Therapeutics (TVTX) Q3 2025 earnings crush expectations, driven by strong FILSPARI sales. Revenue soared 160% year-over-year, sparking an 11.7% stock surge.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

October 30, 2025

Via Benzinga

Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗

October 16, 2025

Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026.

Via Benzinga

Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Growth Momentum and Technical Setup ↗

October 16, 2025

Travere Therapeutics (TVTX) shows strong growth momentum with accelerating earnings and revenue. Its high technical rating and clear setup pattern offer a compelling investment case.

Via Chartmill

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts ↗

September 19, 2025

Via Benzinga

Travere Shares Are Trading Higher Wednesday: What's Going On? ↗

September 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 10, 2025

Via Benzinga

Daktronics, Potbelly, CoreWeave, GameStop And Other Big Stocks Moving Higher On Wednesday ↗

September 10, 2025

Via Benzinga

Why Top 4% Stock, Travere Therapeutics, Skyrocketed To A Three-Year High ↗

September 10, 2025

Shares shot higher Wednesday after the FDA eliminated a key step to a new approval for its drug.

Via Investor's Business Daily

Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application ↗

September 10, 2025

Via Stocktwits

FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari ↗

August 28, 2025

FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.

Via Benzinga

Travere Flirts With A Breakout As FDA Decision Bolsters Filspari's Launch ↗

August 28, 2025

The company has made a name for itself with a drug that treats a progressive kidney condition.

Via Investor's Business Daily

Nvidia To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday ↗

August 28, 2025

Via Benzinga

Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (6 Ratings) ↗

August 28, 2025

Via Benzinga

Viking Global Dumps UnitedHealth, Loads Up On Disney, McDonald's, JPMorgan, AMD In Q2 Shake-Up ↗

August 15, 2025

Via Benzinga

Travere Therapeutics Inc (NASDAQ:TVTX) Surpasses Q2 2025 Expectations with Strong Revenue Growth and Narrower Loss ↗

August 06, 2025

Travere Therapeutics (TVTX) reported strong Q2 2025 results, beating revenue and earnings estimates, driven by FILSPARI sales and milestone payments. Shares rose 2.3% post-earnings.

Via Chartmill

Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews ↗

July 01, 2025

Via Benzinga

7 Analysts Assess Travere Therapeutics: What You Need To Know ↗

June 11, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.